Role of nuclear factor-κB in melanoma

被引:163
作者
Amiri, KI
Richmond, A [1 ]
机构
[1] Dept Vet Affairs, Nashville, TN USA
[2] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA
[3] Meharry Med Coll, Dept Microbiol, Nashville, TN 37208 USA
关键词
nuclear factor-kappa B; melanoma; apoptosis; tumorigenesis; NF-kappa B inhibitors;
D O I
10.1007/s10555-005-1579-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nuclear Factor-kappa B (NF-kappa B) is an inducible transcription factor that regulates the expression of many genes involved in the immune response. Recently, NF-kappa B activity has been shown to be upregulated in many cancers, including melanoma. Data indicate that the enhanced activation of NF-kappa B may be due to deregulations in upstream signaling pathways such as Ras/Raf, PI3K/Akt, and NIK. Multiple studies have shown that NF-kappa B is involved in the regulation of apoptosis, angiogenesis, and tumor cell invasion, all of which indicate the important role of NF-kappa B in tumorigenesis. Thus, understanding the molecular mechanism of melanoma progression will aid in designing new therapeutic approaches for melanoma. In this review, the association between NF-kappa B and melanoma tumorigenesis are discussed. Additionally, the potential of emerging selective NF-kappa B inhibitors for the treatment of melanoma is reviewed.
引用
收藏
页码:301 / 313
页数:13
相关论文
共 123 条
[1]   NF-κB activation [J].
Abraham, E .
CRITICAL CARE MEDICINE, 2000, 28 (04) :N100-N104
[2]   Proteasome inhibition: a novel approach to cancer therapy [J].
Adams, J .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S49-S54
[3]   Progression in cutaneous malignant melanoma is associated with distinct expression profiles -: A tissue microarray-based study [J].
Alonso, SR ;
Ortiz, P ;
Pollán, M ;
Pérez-Gómez, B ;
Sánchez, L ;
Acuña, MJ ;
Pajares, R ;
Martínez-Tello, FJ ;
Hortelano, CM ;
Piris, MA ;
Rodríguez-Peralto, JL .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 164 (01) :193-203
[4]   Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: Implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma [J].
Amiri, KI ;
Horton, LW ;
LaFleur, BJ ;
Sosman, JA ;
Richmond, A .
CANCER RESEARCH, 2004, 64 (14) :4912-4918
[5]   Regulation of NF-κB RelA phosphorylation and transcriptional activity by p21ras and protein kinase Cζ in primary endothelial cells [J].
Anrather, J ;
Csizmadia, V ;
Soares, MP ;
Winkler, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (19) :13594-13603
[6]  
Bakker TR, 1999, INT J CANCER, V80, P320
[7]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[8]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[9]   Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB [J].
Baldwin, AS .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 107 (03) :241-246
[10]   Effect of curcurnin on gelatinase A (MMP-2) activity in B16F10 melanoma cells [J].
Banerji, A ;
Chakrabarti, J ;
Mitra, A ;
Chatterjee, A .
CANCER LETTERS, 2004, 211 (02) :235-242